Acrivon CMO granted 38,817 RSUs

Mirza Mansoor Raza reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Mirza Mansoor Raza reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics, Inc. reported that its Chief Medical Officer, Mirza Mansoor Raza, received an award of 38,817 shares of Common Stock in the form of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share, with 16.67% scheduled to vest on November 18, 2026 and the remaining units vesting in 10 substantially equal quarterly installments thereafter, subject to his continued service. After this grant, he is reported as directly holding 38,817 shares in this award.

Insider Trade Summary

Grant/Award: 38,817 shares

Grant/Award 1 txn

Insider Mirza Mansoor Raza

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	38,817	$0.00	$0.00

Holdings After Transaction: Common Stock — 38,817 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

RSU grant size: 38,817 shares Vesting tranche: 16.67% of RSUs Remaining vesting schedule: 10 quarterly installments +1 more

4 metrics

RSU grant size 38,817 shares Restricted stock units awarded to Chief Medical Officer on May 18, 2026

Vesting tranche 16.67% of RSUs First vesting scheduled for November 18, 2026

Remaining vesting schedule 10 quarterly installments Balance of RSUs vest in substantially equal installments after initial vesting

Holdings after transaction 38,817 shares Total Common Stock reported following the award

Key Terms

restricted stock units ("RSUs"), contingent right, continuous service, Chief Medical Officer

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock"

continuous service financial

"in each case subject to the Reporting Person's continuous service through each such vesting date"

Chief Medical Officer financial

"Mirza Mansoor Raza serves as Chief Medical Officer of Acrivon Therapeutics, Inc."

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Acrivon Therapeutics (ACRV) report for Mirza Mansoor Raza?

Acrivon Therapeutics reported that Chief Medical Officer Mirza Mansoor Raza received 38,817 restricted stock units. Each RSU represents a contingent right to one share of Common Stock, granted at a stated price of $0.00 per share as an equity award.

How many ACRV shares are covered by Mirza Mansoor Raza’s new RSU award?

The award covers 38,817 restricted stock units linked to Acrivon Therapeutics Common Stock. Each RSU converts into one share upon vesting, giving him rights to receive up to 38,817 shares if all vesting conditions are met.

What is the vesting schedule for Mirza Mansoor Raza’s ACRV restricted stock units?

Of the 38,817 RSUs, 16.67% are scheduled to vest on November 18, 2026. The remaining RSUs vest in 10 substantially equal quarterly installments afterward, conditioned on his continuous service through each vesting date.

Is Mirza Mansoor Raza’s ACRV Form 4 transaction an open-market purchase or sale?

The Form 4 shows a grant coded as an acquisition (code A), not an open-market trade. The 38,817 shares were awarded at a stated price of $0.00 per share, reflecting an equity award rather than a market purchase or sale.

How many ACRV shares does Mirza Mansoor Raza hold after this RSU grant?

Following the reported transaction, Mirza Mansoor Raza is shown as directly holding 38,817 shares tied to this award. These are structured as restricted stock units that convert into Common Stock as they vest over the disclosed schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mirza Mansoor Raza

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A(1)		38,817	A	$0	38,817	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)